Monograph Details
|
|
Neoplasms
> Antimetabolites
|
|
FUDR |
| Manufacturer |
|
Mayne |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antimetabolite. |
| Generic Name |
|
Floxuridine 500mg/vial; lyophilized pwd for intra-arterial infusion after reconstitution and dilution. |
| Indications |
|
Palliative therapy of GI adenocarcinoma with liver metastases in select patients (see literature). |
| Children |
|
Not recommended. |
| Adults |
|
Continuous arterial infusion 0.1–0.6mg/kg per day. Hepatic artery infusion: 0.4–0.6mg/kg per day. May give until adverse reactions occur; treat as long as response continues. See literature. |
| Contraindications |
|
Poor nutritional state. Myelosuppression. Serious infections. |
| Precautions |
|
Hospitalize for 1st course. Hepatic or renal dysfunction. History of high-dose pelvic irradiation or alkylation therapy. Monitor blood (esp WBC, platelets). Discontinue for myocardial ischemia, stomatitis or esophagopharyngitis, WBC <3500 or rapidly falling, intractable vomiting, GI ulcer/bleeding, diarrhea, platelets <100000, hemorrhage. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended. |
| Adverse Reactions |
|
GI upset, enteritis, stomatitis, localized erythema, myelosuppression, liver dysfunction, GI bleeding/ulcer, duodenitis, gastroenteritis, glossitis, pharyngitis, intra- and extrahepatic biliary sclerosis, acalculous cholecystitis, alopecia, dermatitis, myocardial ischemia, fever, malaise; lab abnormalities (eg, anemia, leukopenia, thrombocytopenia, abnormal PT, total proteins, ESR, ALT/SGOT, bilirubin, lactic dehydrogenase); procedural complications (eg, arterial aneurysm, ischemia, thrombotic events, fibromyositis, thrombophlebitis, hepatic necrosis, abscess). |
| How Supplied |
|
Vials (5mL)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
